v3.26.1
Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Treasury Stock Amount
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024 [1]   164,087,000        
Beginning balance at Dec. 31, 2024 $ 111,183 $ 19 $ 769,866 $ (1) $ 21 $ (658,722)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 247   247      
Foreign currency translation adjustment 4       4  
Unrealized loss on available-for-sale securities (14)       (14)  
Net loss (11,250)         (11,250)
Ending balance (in shares) at Mar. 31, 2025 [1]   164,087,000        
Ending balance at Mar. 31, 2025 $ 100,170 $ 19 770,113 (1) 11 (669,972)
Beginning balance (in shares) at Dec. 31, 2025 163,519,801 [2] 164,087,000 [3]        
Beginning balance at Dec. 31, 2025 $ 58,011 $ 19 770,423 (1) 39 (712,469)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 155   155      
Foreign currency translation adjustment 33       33  
Unrealized loss on available-for-sale securities (3)       (3)  
Net loss $ (5,938)         (5,938)
Ending balance (in shares) at Mar. 31, 2026 163,519,801 [2] 164,087,000 [3]        
Ending balance at Mar. 31, 2026 $ 52,258 $ 19 $ 770,578 $ (1) $ 69 $ (718,407)
[1] Shares issued and outstanding exclude 738,000 Sponsor Shares subject to vesting requirements.
[2] Shares issued and outstanding exclude 738,000 shares subject to vesting requirements held by TS Innovation Acquisitions Sponsor, L.L.C. (the “Sponsor”) related to the 2021 business combination (the “Sponsor Shares”).
[3] Shares issued and outstanding exclude 738,000 Sponsor Shares subject to vesting requirements.